Oxford Biomedica plc (LON:OXB - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 344.16 ($4.68) and traded as low as GBX 305.50 ($4.16). Oxford Biomedica shares last traded at GBX 311.50 ($4.24), with a volume of 79,517 shares.
Oxford Biomedica Trading Up 1.9%
The business's 50 day simple moving average is GBX 309.65 and its two-hundred day simple moving average is GBX 344.16. The stock has a market cap of £337.51 million, a P/E ratio of -2.36 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48.
Oxford Biomedica (LON:OXB - Get Free Report) last posted its earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.57)) earnings per share for the quarter. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%. As a group, analysts expect that Oxford Biomedica plc will post -31.0799998 EPS for the current year.
Insider Buying and Selling
In other Oxford Biomedica news, insider Heather Preston acquired 11,389 shares of Oxford Biomedica stock in a transaction that occurred on Tuesday, June 17th. The shares were bought at an average price of GBX 324 ($4.41) per share, with a total value of £36,900.36 ($50,231.91). 21.17% of the stock is currently owned by insiders.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
